Albany, NY -- (SBWIRE) -- 05/07/2015 -- Cancer immunotherapy is defined as the treatment that uses patient's immune system to fight against cancer. This is done by stimulating patient's immune system to work against cancer cells or by giving patient's immune system compounds such as man-made immune system proteins to act against cancerous cells. Cancer immunotherapy is sometimes also known as biotherapy or biologic therapy.

Browse Full Report with TOC:
http://www.transparencymarketresearch.com/cancer-immunotherapy-market.html

There are several types of cancer immunotherapies which could be differentiated as follows:

Monoclonal antibodies
Non-specific immunotherapies
Cancer vaccines

Monoclonal antibodies detect antigens such as bacteria, fungi, viruses and parasites resulting in production of antibodies. Monoclonal antibodies forces the immune system to destroy cancer cells, prevent cancer cells from growing rapidly, deliver radiations towards cancerous cells, diagnose cancer and carry powerful drugs to cancerous cells. The major monoclonal antibodies which are approved for cancer immunotherapy include Alemtuzumab (Campath), Bevacizumab (Avastin), Cetuximab (Erbitux) and Ipilimumab (Yervoy). Like monoclonal antibodies, non-specific immunotherapies also assist immune system in destroying cancerous cells. These therapies are provided to cancer patients after chemotherapy or radiation therapy sessions. Most common non-specific immunotherapies in cancer immunotherapy market include interferons and interleukins.

Early buyers will receive 10% customization on reports:
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=4312

Cancer vaccines expose the immune system of the patient to an antigen that stimulates the immune system to recognize and damage protein present in cancer cells, hence damaging the abnormal cells. Cancer vaccines market is further classified into two segments namely prevention vaccines and treatment vaccines. Prevention vaccines are prescribed to the people who are at risk of developing cancer, to prevent the development of any specific type of cancer. For example, Gardasil vaccine prevents the person being infected from human papillomavirus (HPV), a virus which causes cervical cancer. Treatment vaccine however, helps the patient immune system to fight against cancer by training it to recognize and destroy cancer cells. ipuleucel-T (Provenge) is the only FDA approved treatment vaccine in the U.S. which is used for cancer immunotherapy applications.

The cancer immunotherapy market is growing at a faster pace owing to the increasing prevalence of cancer globally. According to World Health Organization (WHO), cancer was the leading cause of death in 2012, accounting for 8.2 million deaths worldwide. Lung, liver, colorectal, stomach and breast cancers were responsible for most of the deaths every year. Statistics also revealed that breast cancer incidence had risen by more than 20% in 2012 from 2009, while breast cancer mortality rate has increased by 14%. Due to harsh lifestyle, excessive intake of alcohol and smoking habits, the incidence of cancer is increasing rapidly worldwide, especially in developed economies of North America and Europe. Increasing morbidity and mortality rate among the cancer patients is fuelling the growth of cancer immunotherapy market. Additionally, the advantage of cancer immunotherapy to perform localized treatment for damaging cancer cells in comparison to radiations or chemotherapy non-targeted therapy is also attracting the oncologists to prescribe for cancer immunotherapy treatment methods. High effectively, less recurrence chances and negligible side effects are the major reasons which will propel the growth of cancer immunotherapy market during forecast period.

Some of the market players operating in cancer immunotherapy market include AstraZeneca, Inc., GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co., Novartis AG, Pfizer, Inc., F. Hoffman-La Roche AG, Advaxis, Inc., Immunomedics, Inc. and Viralytics Ltd.

Read More Report on Pharmaceutical Market:
http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html

About Transparency Market Research
Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR's global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact us:
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: 518-618-1030
USA - Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/